OCULAR THERAPEUTIX, INC Logo

OCULAR THERAPEUTIX, INC

Develops hydrogel drug delivery therapies for eye diseases like wet AMD and glaucoma.

OCUL | NDAQ

Overview

Corporate Details

ISIN(s):
US67576A1007
LEI:
Country:
United States of America
Address:
15 CROSBY DRIVE, 1730 BEDFORD
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Ocular Therapeutix, Inc. is an integrated biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye. The company is committed to redefining the treatment experience for patients with retinal diseases by aiming to reduce the therapeutic burden associated with current standards of care. Its core focus is on its proprietary hydrogel-based drug delivery technology. The lead product candidate, AXPAXLI™ (axitinib intravitreal hydrogel), is an investigational therapy in late-stage clinical development for the treatment of wet age-related macular degeneration (wet AMD). Ocular Therapeutix's pipeline also extends to other ophthalmic conditions, including glaucoma and ocular hypertension.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-11-04 13:25
Quarterly Report
10-Q - OCULAR THERAPEUTIX, INC (0001393434) (Filer)
English 1.5 MB
2025-11-04 13:19
Regulatory News Service
8-K - OCULAR THERAPEUTIX, INC (0001393434) (Filer)
English 177.7 KB

Automate Your Workflow. Get a real-time feed of all OCULAR THERAPEUTIX, INC filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for OCULAR THERAPEUTIX, INC

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for OCULAR THERAPEUTIX, INC via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Company Country Ticker View
Adicet Bio, Inc. Logo
Developing off-the-shelf gamma delta T cell therapies for cancer and autoimmune diseases.
United States of America ACET
Adlai Nortye Ltd. Logo
Clinical-stage biopharma developing innovative targeted and immuno-oncology therapies.
United States of America ANL
ADMA BIOLOGICS, INC. Logo
End-to-end biopharma making plasma-derived biologics for immune-compromised patients.
United States of America ADMA
Adverum Biotechnologies, Inc. Logo
Developing single-injection gene therapies for prevalent ocular diseases like wet AMD.
United States of America ADVM
Advicenne Logo
Develops and commercializes therapies for rare renal diseases for patients of all ages.
France ALDVI
AegirBio AB Logo
Develops user-friendly, saliva-based tests for health monitoring & therapeutic drug monitoring.
Sweden AEGIR
Aelis Farma Logo
Developing novel CB1 receptor inhibitors for treating brain and CNS disorders.
France AELIS
AEON Biopharma, Inc. Logo
Developing therapeutic neurotoxins for medical conditions like migraines and cervical dystonia.
United States of America AEON
AFC-HD AMS Life Science Co.,Ltd. Logo
An OEM of health foods, supplements, and cosmetics, managing the full value chain from R&D to sales.
Japan 2927
AGENUS INC Logo
Develops antibodies, cell therapies & adjuvants to harness the immune system against cancer.
United States of America AGEN

Talk to a Data Expert

Have a question? We'll get back to you promptly.